Immunotherapy with chemo and targeted drug for colon cancer in the belly
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests serplulimab (immunotherapy) combined with FOLFIRI chemo plus bevacizumab for colon cancer that has spread to the lining of the abdomen (peritoneal metastases). It aims to shrink these tumors and improve outcomes when surgery can’t fully remove them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed colon cancer in biopsy tissue, and it matches pMMR/MSS and RAS/BRAF “wild-type” test results
- Your scans show colon cancer has spread to the belly lining (peritoneal metastases)
- Doctors found tumor tissue during surgery that could not be fully removed (not CC0/1)
- You’re age 18–75, and you can do day-to-day activities fairly well (ECOG 0–2), with an expected survival of more than 12 weeks
- Your blood counts, kidney function, and liver tests are in acceptable ranges for treatment
- You can safely handle immunotherapy, chemotherapy, and surgery, and you can sign the study consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
This trial tests whether giving a combination of chemotherapy, radiation, and two newer drugs (an immunotherapy and an anti-angiogenesis drug) before surgery can improve outcomes for people with locally advanced rectal cancer. If you qualify, you would receive this treatment for a few months, and then have surgery.
This trial tests a combination of three drugs—chemotherapy plus two targeted therapies—as a first treatment for colorectal cancer that cannot be surgically removed. The goal is to shrink tumors enough to allow surgery later, potentially improving outcomes.
This trial tests a combination of three drugs (serplulimab, bevacizumab, and a chemotherapy regimen) for people with pancreatic cancer that has spread or cannot be removed. It is for those who have already had one prior treatment and aims to see if this new combination can help control the cancer.
This trial combines a special type of radiation, immunotherapy, a targeted blood-vessel drug, and a chemotherapy pill for patients whose colorectal cancer has continued to grow after two prior treatments. The hope is that this combination can shrink tumors or slow down the cancer better than current options.
Hear when a new Unresectable Colon Cancer Peritoneal Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.